Last reviewed · How we verify

Edaravone Dexborneol Sublingual Tablets

Peking Union Medical College Hospital · Phase 3 active Small molecule

Edaravone is a free radical scavenger that reduces oxidative stress and neuroinflammation, while dexborneol enhances absorption and bioavailability through sublingual delivery.

Edaravone is a free radical scavenger that reduces oxidative stress and neuroinflammation, while dexborneol enhances absorption and bioavailability through sublingual delivery. Used for Acute ischemic stroke.

At a glance

Generic nameEdaravone Dexborneol Sublingual Tablets
SponsorPeking Union Medical College Hospital
Drug classFree radical scavenger with permeation enhancer
TargetHydroxyl radicals and reactive oxygen species (ROS)
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Edaravone works by neutralizing hydroxyl radicals and other reactive oxygen species that accumulate during acute ischemic stroke, thereby limiting neuronal damage and apoptosis. Dexborneol, a natural monoterpene alcohol, acts as a permeation enhancer that improves the sublingual absorption of edaravone, allowing for faster systemic delivery and potentially improved clinical efficacy compared to intravenous administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: